Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2022 Earnings Presentation
17 slides from Alkem Laboratories's earnings presentation, Aug 6, 2021
Slide 1: Cover letter to stock exchanges
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.corT, • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 06 th August, 2021 The Co
Slide 2: Press Release: Alkem reports Q1FY22 results
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www .alkemlabs com • CIN : L00305MH1973PLC174201 Press Release Alkem repor
Slide 3: Press Release: therapy segment performance and R&D
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax : 022-2495 2955 • Email : contact@alkem .com • Website : www alkemlabs.com • GIN : L00305MH1973PLC174201 cardiac and derma also
Slide 4: Update on US FDA Inspections
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai · 400 013, Maharashtra, India. • Phone : +91-22-3982 9999 • Fax : 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Update on US FDA Inspecti
Slide 5: Q1FY22 Conference Call details
<8> ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone : +91-22-3982 9999 • Fax : 022-2495 2955 ALKEM • Email : contact@alkem.com • Website : www alkemlabs.com • CIN : L00305MH1973PLC174201 Q1FY22 Conference Call
Slide 6: Q1FY22 Alkem presentation, August 6, 2021
I l l l l lilt-: ii - Iii. •• -~ 111111 ALKEM ~ Ill p!l!IIII r-rt ~ :W-----'- Investor Presentation Q1FY22 August 6, 2021
Slide 7: Safe Harbor Statement
<a> ALKEM Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assump
Slide 8: Key Highlights of Q1FY22
<a> Key Highlights of Q1FY22 ALKEM Good start to the financial year with strong growth in the India Business • Revenue from Operations grew by 37.1% YoY during the quarter, with EBITDA margin of 21.7% and Net Profit growth of 10.9% YoY • India Business: Company’s secondary sales registered growth of
Slide 9: Key Financial Highlights – Q1FY22 (Consolidated)
<a> Key Financial Highlights – Q1FY22 (Consolidated) ALKEM All figures in ₹ mn Revenue from Operations India sales ! I 19,097 ! 27,314 I ! l 11,550 I ! 19,920 I lI ! Q1FY21 Q1FY22 I I ! International sales l I YoY:0.6% 7,903 7,853 I ! \ I ! I Q1FY21 Q1FY22 ! l! ! : Q1FY21 Q1FY22
Slide 10: Key Financial Highlights – Q1FY22 (Consolidated)
<a> Key Financial Highlights – Q1FY22 (Consolidated) ALKEM All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 16,366 5,929 12,581 5,217 21.7% 63.2% 59.9% !' '--------------] 26.2% ' Q1FY21 Q1FY22 I Q1FY21 Q1FY22 I -------------------t----------------------------------- i ----
Slide 11: India Business
<a> India Business ALKEM India Business: Q1FY22 Sales of ₹ 19,097 million (65.3% YoY growth) • India sales contributed 70.7% to total sales in Q1FY22 • In Q1FY22, the Company’s secondary sales grew by 61.1% YoY compared to IPM growth of 39.2% YoY (Source: IQVIA data) • Growth was mainly led by acute
Slide 12: Secondary Sales Performance
<a> Secondary Sales Performance ALKEM Robust growth across all the major therapeutic segments in Q1FY22 -1 +2 Market rank 1 3 4 2 Acute Therapies 88.5% 93.6% 86.6% 43.7% 46.8% 32.8% 33.2% 36.3% - Anti-infectives Alkem sales growth YoY1,2 +2 Gastro-intestinal +3 - Pain/ Analgesics Vitamins/ Minerals
Slide 13: US Business
<a> US Business ALKEM US Business: Q1FY22 Sales of ₹ 6,043 million (YoY decline of 9.3%) • US sales contributed 22.4% to total sales in Q1FY22 • During the quarter, the US business registered sequential growth of 11.2% over Q4FY21 • In Q1FY22, the Company filed 2 ANDAs with the US FDA and received 5
Slide 14: US Business: Update on US FDA inspections
<a> US Business ALKEM Update on US FDA inspections Facility Capability Last inspection Status post last inspection Received 2 observations. Already sent a detail response to the St. Louis (US) Formulations June 2021 US FDA on the corrective and preventive actions being taken Baddi (India) Formulatio
Slide 15: Other International Business
<a> Other International Business ALKEM Other International Business: Q1FY22 Sales of ₹ 1,860 million (56.4% YoY growth) • Other International Market sales contributed 6.9% to total sales in Q1FY22 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key m
Slide 16: Latest Shareholding Pattern
<a> Latest Shareholding Pattern ALKEM Shareholding pattern as on June 30, 2021 Non-Institution, 22.17% Promoter & Promoter Group, 58.84% Institution, 18.99% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, O
Slide 17: Thank You
<a> ALKEM Thank You For further information or queries, please contact Gagan Borana Investor Relations Tel: +91 22 3982 9960 E-mail: gagan.borana@alkem.com